 Non-concurrent controls have become increasingly important in clinical research, due to their ability to reduce the cost and duration of clinical trials. However, there is no consensus regarding the best way to incorporate them into platform trials. This paper provides an overview of the current state of the art in terms of statistical methodologies and regulatory guidance for the use of non-concurrent controls in platform trials. This article was authored by Marta Bofill-Royg, Kora Bergwinkel, Ursula Garturek and others.